We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
-1.61%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$21M
Cap. Flow
+$284M
Cap. Flow %
244.1%
Top 10 Hldgs %
42.12%
Holding
462
New
171
Increased
79
Reduced
68
Closed
122

Top Buys

1
MDVN
MEDIVATION, INC.
MDVN
+$4.59M
2
BIIB icon
Biogen
BIIB
+$3.56M
3
CALM icon
Cal-Maine
CALM
+$2.79M
4
BMY icon
Bristol-Myers Squibb
BMY
+$2.48M
5
AAPL icon
Apple
AAPL
+$2.33M

Top Sells

1
BAX icon
Baxter International
BAX
+$4.11M
2
GILD icon
Gilead Sciences
GILD
+$2M
3
IBM icon
IBM
IBM
+$1.48M
4
CMG icon
Chipotle Mexican Grill
CMG
+$930K
5
EXPE icon
Expedia Group
EXPE
+$914K

Sector Composition

1 Healthcare 41.4%
2 Technology 6.27%
3 Consumer Staples 4.14%
4 Consumer Discretionary 2.26%
5 Materials 1.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WMT icon
101
CALL
Walmart Inc
WMT
$915B
$217K 0.19%
285,000
– –
IMPV
102
DELISTED
Imperva, Inc.
IMPV
$211K 0.18%
+4,916
New +$206K
IRBT
103
DELISTED
iRobot
IRBT
$206K 0.18%
+5,881
New +$216K
CYTO
104
DELISTED
Altamira Therapeutics Ltd
CYTO
$205K 0.18%
+1
New +$299K
TCOM icon
105
Trip.com Group
TCOM
$27.5B
$204K 0.18%
+4,947
New +$216K
SRPT icon
106
CALL
Sarepta Therapeutics
SRPT
$1.82B
$203K 0.17%
43,500
-64,200
-60% -$1.19M
ESPR
107
CALL
DELISTED
Esperion Therapeutics
ESPR
$195K 0.17%
85,500
-6,700
-7% -$111K
LGND icon
108
PUT
Ligand Pharmaceuticals
LGND
$5.94B
$189K 0.16%
32,060
-8,015
-20% -$595K
MDVN
109
CALL
DELISTED
MEDIVATION, INC.
MDVN
$189K 0.16%
42,100
-8,000
-16% -$454K
BMY icon
110
CALL
Bristol-Myers Squibb
BMY
$124B
$173K 0.15%
50,000
+30,100
+151% +$2.13M
CPB icon
111
CALL
Campbell Soup
CPB
$6.75B
$173K 0.15%
53,900
+37,800
+235% +$2.37M
ISEE
112
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$170K 0.15%
+11,300
New +$561K
TCRT icon
113
Alaunos Therapeutics
TCRT
$5.06M
$165K 0.14%
+200
New +$218K
TGT icon
114
CALL
Target
TGT
$63.7B
$165K 0.14%
+70,000
New +$5.22M
SVVC
115
DELISTED
Firsthand Technology Value Fund, Inc. Common Stock
SVVC
$165K 0.14%
22,238
– –
IONS icon
116
CALL
Ionis Pharmaceuticals
IONS
$9.03B
$164K 0.14%
+175,300
New +$5.65M
TXN icon
117
CALL
Texas Instruments
TXN
$265B
$162K 0.14%
69,200
+54,100
+358% +$3.22M
AMGN icon
118
CALL
Amgen
AMGN
$201B
$157K 0.13%
55,000
+2,100
+4% +$326K
RVNC
119
DELISTED
Revance Therapeutics, Inc.
RVNC
$157K 0.13%
+11,577
New +$205K
ATHM icon
120
PUT
Autohome
ATHM
$2.51B
$154K 0.13%
19,000
-2,700
-12% -$72.2K
LRMR icon
121
Larimar Therapeutics
LRMR
$381M
$149K 0.13%
2,078
-3,709
-64% -$293K
SHPG
122
CALL
DELISTED
Shire pic
SHPG
$147K 0.13%
+20,000
New +$3.61M
SPY icon
123
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$146K 0.13%
294,000
+159,000
+118% +$33M
PRTK
124
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$139K 0.12%
+10,000
New +$147K
CXRX
125
DELISTED
Concordia International Corp. Common Stock
CXRX
$139K 0.12%
+6,471
New +$170K
3 4
5
6 7

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q2 2016 Portfolio in Review

As of Q2 2016, FT Options held 462 positions worth $116M, up 22% from $95.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

FT Options deployed $284M of net new capital in Q2 2016, opening 171 new positions and adding to 79 existing holdings. Its largest new stake was Bristol-Myers Squibb: 35,075 shares worth $2.58M.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Staples.

On the sell side, the largest reduction was Gilead Sciences, an estimated $2M trimmed.

  • FT Options's largest Q2 2016 buy was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
  • FT Options added most to MEDIVATION, INC. in Q2 2016, an estimated $4.59M increase.
  • FT Options's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $2M.
  • FT Options fully exited Baxter International in Q2 2016, selling an estimated $4.11M.
  • FT Options's ten largest holdings make up 42% of its $116M portfolio in Q2 2016.
  • FT Options opened 171 new positions and closed 122 in Q2 2016.
  • FT Options's portfolio value rose 22% quarter-over-quarter to $116M.

Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.